Nuvectis Pharma
NVCT
53 hedge funds and large institutions have $22.2M invested in Nuvectis Pharma in 2025 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
13% more funds holding
Funds holding: 47 → 53 (+6)
1.01% less ownership
Funds ownership: 15.52% → 14.51% (-1%)
8% less capital invested
Capital invested by funds: $24.2M → $22.2M (-$1.97M)
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$313K |
| 2 |
Goldman Sachs
New York
|
+$310K |
| 3 |
BlackRock
New York
|
+$291K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$278K |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$226K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$364K |
| 2 |
Millennium Management
New York
|
-$233K |
| 3 |
BBI
Baxter Bros Inc
Riverside,
Connecticut
|
-$112K |
| 4 |
MG
Marex Group
London,
|
-$112K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$108K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAP
51
Arax Advisory Partners
Denver,
Colorado
| $229 | +$261 | +38 | New |
|
|
SCM
52
Sterling Capital Management
Charlotte,
North Carolina
| $187 | – | – | – |
|
|
53
Millennium Management
New York
| – | -$233K | -31,167 | Closed |
|
|
BBI
54
Baxter Bros Inc
Riverside,
Connecticut
| – | -$112K | -15,000 | Closed |
|
|
MG
55
Marex Group
London,
| – | -$112K | -15,000 | Closed |
|
56
Simplex Trading
Chicago,
Illinois
| – | -$14.5K | -2,114 | Closed |
|
57
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$241 | +35 | New |
|
NVCT Hedge Fund Activity: Q3 2025 in Review
53 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q3 2025, worth a combined $22.2M — down 8.1% from $24.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NVCT positions and 5 closed out — a net gain of 6 holders — while 13 added to existing stakes and 15 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $313K. The largest seller was Marshall Wace, cutting an estimated $364K.
- 53 institutional investors held Nuvectis Pharma (NVCT) as of Q3 2025, up from 47 in Q2 2025.
- Funds reported $22.2M of Nuvectis Pharma stock for Q3 2025, down 8.1% quarter-over-quarter.
- 11 funds opened new Nuvectis Pharma positions in Q3 2025 and 5 closed out, a net change of +6 holders.
- The largest Nuvectis Pharma buyer in Q3 2025 was Susquehanna International Group, an estimated $313K added.
- The largest Nuvectis Pharma seller in Q3 2025 was Marshall Wace, an estimated $364K sold.
Based on aggregated 13F filings for Q3 2025.